Literature DB >> 2006699

Controlled discontinuation of benzodiazepine treatment for patients with panic disorder.

R Noyes1, M J Garvey, B Cook, M Suelzer.   

Abstract

OBJECTIVE: The purpose of this study was to compare the effects of discontinuing treatment with intermediate- and long-acting benzodiazepines.
METHOD: Fifty patients with panic disorder who had taken part in a double-blind treatment study and had responded to alprazolam, diazepam, or placebo for 8 months were asked to stop taking these medications gradually.
RESULTS: After a relatively rapid dose reduction, the majority of patients relapsed. Rebound anxiety and withdrawal symptoms were identified in a substantial minority of patients. Those who were taking alprazolam showed earlier and more intense rebound anxiety and withdrawal symptoms than did the patients who received diazepam. Both the level of pretreatment anxiety and the drug the patient was taking predicted the level of anxiety when drug treatment was discontinued.
CONCLUSIONS: The findings indicate that withdrawal phenomena commonly occur after patients stop taking benzodiazepines and that they are more frequent after discontinuation of treatment with shorter-acting drugs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2006699     DOI: 10.1176/ajp.148.4.517

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  12 in total

Review 1.  Anxiety in primary care.

Authors:  Kristen Hope Demertzis; Michelle G Craske
Journal:  Curr Psychiatry Rep       Date:  2006-08       Impact factor: 5.285

2.  Center Predictors of Long-Term Benzodiazepine Use in Chronic Obstructive Pulmonary Disease and Post-traumatic Stress Disorder.

Authors:  Lucas M Donovan; Carol A Malte; Laura J Spece; Matthew F Griffith; Laura C Feemster; Steven B Zeliadt; David H Au; Eric J Hawkins
Journal:  Ann Am Thorac Soc       Date:  2019-09

3.  Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation.

Authors:  Michael W Otto; R Kathryn McHugh; Naomi M Simon; Frank J Farach; John J Worthington; Mark H Pollack
Journal:  Behav Res Ther       Date:  2010-04-28

4.  A pilot open trial of brief psychodynamic psychotherapy for panic disorder.

Authors:  B Milrod; F Busch; A C Leon; A Aronson; J Roiphe; M Rudden; M Singer; T Shapiro; H Goldman; D Richter; M K Shear
Journal:  J Psychother Pract Res       Date:  2001

Review 5.  New developments in panic disorder.

Authors:  P C Marzol; M H Pollack
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

Review 6.  Current benzodiazepine issues.

Authors:  J H Woods; G Winger
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

7.  The dependence potential of short half-life benzodiazepines: a meta-analysis.

Authors:  D D Hallfors; L Saxe
Journal:  Am J Public Health       Date:  1993-09       Impact factor: 9.308

Review 8.  Generalised anxiety disorder: treatment options.

Authors:  John J Sramek; Victoria Zarotsky; Neal R Cutler
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 9.  Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.

Authors:  Suyash Prasad; Chris Steer
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

10.  Attending to emotional cues for drug abuse: bridging the gap between clinic and home behaviors.

Authors:  Michael W Otto; Conall M O' Cleirigh; Mark H Pollack
Journal:  Sci Pract Perspect       Date:  2007-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.